European Journal of Molecular & Clinical Medicine

Aim: Purpose of the present research was to assess the outcome of dental implant success in HIV positive patients.
Methodology: Twenty patients testing positive for the human immunodeficiency virus were recruited for this study. Twenty-one negative control patients were also selected, for a total of 41 patients. Diagnostic impressions were collected and cone beam computed tomography images were obtained. Implant size and positioning were planned using cone beam computed tomography software. Two stage or single surgery was performed as determined by the surgeon (periodontist). After a six month healing period, definitive impressions were fabricated using polyvinyl siloxane impression material. Implant stability quotient values were obtained at the time of surgery and placement of the restoration. Screw retained custom titanium abutments were designed, milled, and placed with 25 N·cm torque using a calibrated torque controller. Porcelain fused-to-metal complete coverage restorations were then cemented with elastomeric resin implant cement. Implants and restorations were assessed at 6 month intervals over a period of 3 years for stability, peri-implant health, and patient satisfaction.
Results: Over the three year period, 25 of 42 implants placed in the negative control group were assessed, and 17 of 27 implants placed in the positive control group were evaluated. The overall patient retention rate was 77 percent. At the three year follow up, restorations examined were fully functional and causing no pain. Overall implant retention within the positive group was 96 percent. Implant retention within the negative control group was 100 percent. No differences were noted between groups for bone loss based on statistical tests.
Conclusion: Within the limitations of this clinical investigation, the presence of human immunodeficiency virus per se was not a contraindication to dental treatment with implant-supported restorations.

Background:
Advanced intermittent hypoxia-normoxia KZ-001 (manufactured in Japan under the
Japanese Wellness Science and Technology) is a combination of a fine-tuned
hypobaric (hypoxia) and hyperbaric (hyperoxia) chamber. It is a new Japanese method
that uses both aerospace and high-terrestrial altitude research or training to stimulate
the effects of high altitude on the human body, especially hypoxia and hyperoxia.
Objectives:
This study aimed to test two hypotheses in response to advanced intermittent hypoxianormoxia
KZ-001 stratification based on its mechanism of action and to answer the
following clinical question: Do patients’ glycated hemoglobin (HbA1c) levels decrease
when undergoing advanced intermittent hypoxia-normoxia KZ-001 treatment?